Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32

Benzinga Newsdesk www.benzinga.com Positive 79.7%

Neg 0% Neu 0% Pos 79.7%

Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.